Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.41 |
| ▸ | HTR2C | P28335 | 7/20 | 0.41 |
| ▸ | HTR2B | P41595 | 7/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297610 | 0.83 | SMN1; SMN2 (0.53) | HTR2AHTR2CHTR2BPOLBHSD11B1 | |
| SCHEMBL2357556 | 0.83 | HTR2A (0.38) | HTR2AHTR2CHTR2BPOLBSMN1; SMN2 | |
| SCHEMBL2300018 | 0.81 | HTR2A (0.36) | HTR2AHTR2CHTR2BPOLB | |
| SCHEMBL4738514 | 0.77 | HTR2A (0.34) | HTR2AHTR2CHTR2BPOLBGPR119 | |
| SCHEMBL5377547 | 0.77 | CHRNB2 (0.39) | — | |
| SCHEMBL27561229 | 0.77 | SLC6A2 (0.44) | HTR2AHTR2CHTR2BGPR119 | |
| SCHEMBL4143683 | 0.76 | HTR1A (0.41) | HTR2AHTR2CPOLBSSTR4 | |
| SCHEMBL3567298 | 0.76 | KDM4E (0.41) | POLBSMN1; SMN2 | |
| SCHEMBL3453910 | 0.76 | SSTR4 (0.34) | HTR2AHTR2CHTR2BSSTR4 | |
| SCHEMBL6992310 | 0.75 | HTR2C (0.39) | HTR2AHTR2CHTR2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9421204-B2 | Oligomer modified diaromatic substituted compounds | NEKTAR THERAPEUTICS (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160143904-A1 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS | NEKTAR THERAPEUTICS | 2016-05-26 | — | — | US | disclosed |
| US-9226970-B2 | Oligomer modified diaromatic substituted compounds | NEKTAR THERAPEUTICS (US) | 2016-01-05 | — | — | US | disclosed |
| US-20130040961-A1 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011103559-A1 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2011-08-25 | — | — | WO | disclosed |
| US-4996318-A | Amino-9,10-secosteroids useful for treating head injury, spinal cord trauma or stroke | THE UPJOHN COMPANY (US) | 1991-02-26 | — | — | US | disclosed |
| EP-0354920-A1 | AMINO-9,10-SECOSTEROIDS | THE UPJOHN COMPANY (US) | 1990-02-21 | — | — | EP | disclosed |
| WO-1988007527-A1 | AMINO-9,10-SECOSTEROIDS | THE UPJOHN COMPANY (US) | 1988-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040961-A1 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS | PCNA, DNPEP, POLI | HTR2A 3211/4885HTR2C 3080/4885HTR2B 3371/4885 |
| US-20160143904-A1 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS | HLA-DRB1, NOD2, DCX | HTR2A 2032/4885HTR2C 1767/4885HTR2B 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.